A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.

开始日期2024-02-20

申办/合作机构

Novartis Pharmaceuticals Corp.

CTRI/2024/01/061272 / Recruiting临床2期

A randomized, participant- and investigator-blinded, placebo-controlled, parallel group study to assess the efficacy, safety and pharmacokinetics of EYU688 in patients with dengue fever - NIL

开始日期2024-02-15

申办/合作机构

Novartis Healthcare Pvt Ltd.

100 项与 EYU-688 相关的临床结果

登录后查看更多信息

100 项与 EYU-688 相关的转化医学

登录后查看更多信息

100 项与 EYU-688 相关的专利（医药）

登录后查看更多信息

项与 EYU-688 相关的文献（医药）

Molecules

Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition

Review

作者: Feiters, Martin C. ; Gironés, Daniel ; Cavina, Lorenzo ; Bouma, Mathijs J.

Orthoflaviviruses, including zika (ZIKV), West Nile (WNV), and dengue (DENV) virus, induce severely debilitating infections and contribute significantly to the global disease burden, yet no clinically approved antiviral treatments exist. This review offers a comprehensive analysis of small-molecule drug development targeting orthoflaviviral infections, with a focus on NS2B-NS3 inhibition. We systematically examined clinical trials, preclinical efficacy studies, and modes of action for various viral replication inhibitors, emphasizing allosteric and orthosteric drugs inhibiting NS2B-NS3 protease with in vivo efficacy and in vitro-tested competitive NS2B-NS3 inhibitors with cellular efficacy. Our findings revealed that several compounds with in vivo preclinical efficacy failed to show clinical antiviral efficacy. NS3-NS4B inhibitors, such as JNJ-64281802 and EYU688, show promise, recently entering clinical trials, underscoring the importance of developing novel viral replication inhibitors targeting viral machinery. To date, the only NS2B-NS3 inhibitor that has undergone clinical trials is doxycycline, however, its mechanism of action and clinical efficacy as viral growth inhibitor require additional investigation. SYC-1307, an allosteric inhibitor, exhibits high in vivo efficacy, while temoporfin and methylene blue represent promising orthosteric non-competitive inhibitors. Compound 71, a competitive NS2B-NS3 inhibitor, emerges as a leading preclinical candidate due to its high cellular antiviral efficacy, minimal cytotoxicity, and favorable in vitro pharmacokinetic parameters. Challenges remain in developing competitive NS2B-NS3 inhibitors, including appropriate biochemical inhibition assays as well as the selectivity and conformational flexibility of the protease, complicating effective antiviral treatment design.

100 项与 EYU-688 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
登革热	临床2期	新加坡	Novartis Pharmaceuticals Corp.	2024-02-20
登革热	临床2期	马来西亚	Novartis Pharmaceuticals Corp.	2024-02-20
登革热	临床2期	印度	Novartis Pharmaceuticals Corp.	2024-02-20